Vyluma Meets With FDA On Atropine Sulfate For Pediatric Myopia
18 Jun 2024 //
GLOBENEWSWIRE
Vyluma Announces MAA Validation For European Union
29 May 2024 //
GLOBENEWSWIRE
Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002
11 Oct 2023 //
GLOBENEWSWIRE
Vyluma Announces FDA Acceptance of New Drug Application for NVK002
06 Jun 2023 //
GLOBENEWSWIRE
Vyluma to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002
27 Oct 2022 //
GLOBENEWSWIRE
Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III
01 Sep 2022 //
GLOBENEWSWIRE